The Path Forward for Infused Biosimilars in the US
Vibhu Tewary offers insight on this market segment, including a behind-the-scenes of what goes into designing a report.
In this exclusive PC Podcast interview, Vibhu Tewary, project director, IQVIA Institute for Human Data Science, discusses:
- Highlights of the company’s report surrounding the “Long-term Market Sustainability for Infused Biosimilars in the US: Foundational Analytics on Emerging Risks to Sustainability”
- The process that constructing and piecing together a report of this magnitude entails, along with where the idea itself came from
- The concept of net cost recovery
- The ongoing challenges surrounding ASP-based reimbursement
- A closed-door, multi-stakeholder virtual roundtable (based on his original report) that was previously held
The latest episode of The Pharmaceutical Commerce Podcast is available directly on Audioboom, Spotify, or iHeart.
Recent Videos
Related Content
Newron, Myung In Pharm Form Partnership Centered Around Treating Schizophrenia in South Korea
January 14th 2025Article
The license agreement will feature an upcoming Phase III trial and—depending on results—the development, manufacturing, and commercialization of evenamide as a potential treatment option.
